PCI术后1个月双联抗血小板治疗后改用氯吡格雷 vs 12个月双联抗血小板治疗对心血管和出血事件的影响:STOPDAPT-2随机临床试验
STOPDAPT-2为多中心、开放标签、随机临床试验,纳入日本90家医院2015年12月至2017年12月接受PCI的3045例患者,随机分为1个月DAPT后氯吡格雷单药组(n=1523)或12个月阿司匹林联合氯吡格雷DAPT组(n=1522)。主要终点为12个月心血管死亡、心肌梗死、缺血性或出血性卒中、确定性支架血栓或大/小出血的复合终点,相对非劣效界值50%。1个月DAPT组主要终点发生率为2.36%,12个月DAPT组为3.70%(绝对差-1.34%[95%CI -2.57%至-0.11%];HR 0.64[95%CI 0.42-0.98]),满足非劣效(P<.001)和优效(P=.04)。主要次要出血终点1个月DAPT组0.41% vs 12个月DAPT组1.54%(HR 0.26[95%CI 0.11-0.64];优效性P=.004);主要次要心血管终点1.96% vs 2.51%(HR 0.79[95%CI 0.49-1.29]),满足非劣效(P=.005)但未达优效(P=.34)。作者认为较短DAPT疗程可能带来获益,但鉴于研究局限,需在其他人群中进一步研究。
要点
- PCI术后1个月DAPT后氯吡格雷单药 vs 12个月阿司匹林+氯吡格雷DAPT:主要复合终点2.36% vs 3.70%,HR 0.64(95%CI 0.42-0.98),非劣效P<.001且优效P=.04。
- 主要次要出血终点:1个月DAPT组0.41% vs 12个月DAPT组1.54%,HR 0.26(95%CI 0.11-0.64),优效性P=.004。
- 主要次要心血管终点:1个月DAPT组1.96% vs 12个月DAPT组2.51%,HR 0.79(95%CI 0.49-1.29),非劣效P=.005但未达优效P=.34。
- 研究为日本90家医院多中心开放标签RCT,3045例随机,3009例中2974例(99%)完成试验。
- 作者认为较短DAPT疗程可能带来获益,但鉴于研究局限,需在其他人群中进一步研究。
适用人群与场景
- 在日本90家医院接受PCI的患者,2015年12月至2017年12月入组,随机3045例。
- 最终分析人群为3009例(36例撤回知情同意),其中2974例(99%)完成试验。
处置流程与药物剂量
- 1个月DAPT后氯吡格雷单药治疗组(n=1523):DAPT方案原文未写明具体药物组成,1个月后改为氯吡格雷单药。
- 12个月DAPT组(n=1522):阿司匹林联合氯吡格雷治疗12个月。
研究设计与关键结果
- 研究类型:多中心、开放标签、随机临床试验;日本90家医院;随机3045例,分析3009例,2974例(99%)完成试验。
- 主要终点(12个月心血管死亡、心肌梗死、缺血性或出血性卒中、确定性支架血栓或大/小出血复合终点):1个月DAPT组2.36% vs 12个月DAPT组3.70%,绝对差-1.34%(95%CI -2.57%至-0.11%),HR 0.64(95%CI 0.42-0.98),非劣效P<.001,优效P=.04。
- 主要次要心血管终点(心血管死亡、心肌梗死、缺血性或出血性卒中或确定性支架血栓):1个月DAPT组1.96% vs 12个月DAPT组2.51%,绝对差-0.55%(95%CI -1.62%至0.52%),HR 0.79(95%CI 0.49-1.29),非劣效P=.005,优效P=.34。
- 主要次要出血终点(大或小出血):1个月DAPT组0.41% vs 12个月DAPT组1.54%,绝对差-1.13%(95%CI -1.84%至-0.42%),HR 0.26(95%CI 0.11-0.64),优效性P=.004。
- 非劣效界值为相对50%。
证据类型、等级与局限
- 证据类型:多中心、开放标签、随机临床试验(RCT)。
- 作者结论:1个月DAPT后氯吡格雷单药较12个月DAPT显著降低心血管与出血复合事件发生率,满足非劣效和优效标准。
- 局限:作者指出鉴于研究局限,需在其他人群中进一步研究。
对床旁实践的改变
- 在接受PCI的患者中,与12个月阿司匹林联合氯吡格雷DAPT相比,1个月DAPT后氯吡格雷单药治疗12个月复合心血管与出血事件发生率更低(2.36% vs 3.70%,HR 0.64)。
- 作者认为较短DAPT疗程可能带来获益,但鉴于研究局限,需在其他人群中进一步研究。
指南或共识出处
- STOPDAPT-2随机临床试验,ClinicalTrials.gov标识NCT02619760。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Very short mandatory dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with a drug-eluting stent may be an attractive option.
OBJECTIVE: To test the hypothesis of noninferiority of 1 month of DAPT compared with standard 12 months of DAPT for a composite end point of cardiovascular and bleeding events.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter, open-label, randomized clinical trial enrolling 3045 patients who underwent PCI at 90 hospitals in Japan from December 2015 through December 2017. Final 1-year clinical follow-up was completed in January 2019.
INTERVENTIONS: Patients were randomized either to 1 month of DAPT followed by clopidogrel monotherapy (n=1523) or to 12 months of DAPT with aspirin and clopidogrel (n=1522).
MAIN OUTCOMES AND MEASURES: The primary end point was a composite of cardiovascular death, myocardial infarction (MI), ischemic or hemorrhagic stroke, definite stent thrombosis, or major or minor bleeding at 12 months, with a relative noninferiority margin of 50%. The major secondary cardiovascular end point was a composite of cardiovascular death, MI, ischemic or hemorrhagic stroke, or definite stent thrombosis and the major secondary bleeding end point was major or minor bleeding.
RESULTS: Among 3045 patients randomized, 36 withdrew consent; of 3009 remaining, 2974 (99%) completed the trial. One-month DAPT was both noninferior and superior to 12-month DAPT for the primary end point, occurring in 2.36% with 1-month DAPT and 3.70% with 12-month DAPT (absolute difference, -1.34% [95% CI, -2.57% to -0.11%]; hazard ratio [HR], 0.64 [95% CI, 0.42-0.98]), meeting criteria for noninferiority (P < .001) and for superiority (P = .04). The major secondary cardiovascular end point occurred in 1.96% with 1-month DAPT and 2.51% with 12-month DAPT (absolute difference, -0.55% [95% CI, -1.62% to 0.52%]; HR, 0.79 [95% CI, 0.49-1.29]), meeting criteria for noninferiority (P = .005) but not for superiority (P = .34). The major secondary bleeding end point occurred in 0.41% with 1-month DAPT and 1.54% with 12-month DAPT (absolute difference, -1.13% [95% CI, -1.84% to -0.42%]; HR, 0.26 [95% CI, 0.11-0.64]; P = .004 for superiority).
CONCLUSIONS AND RELEVANCE: Among patients undergoing PCI, 1 month of DAPT followed by clopidogrel monotherapy, compared with 12 months of DAPT with aspirin and clopidogrel, resulted in a significantly lower rate of a composite of cardiovascular and bleeding events, meeting criteria for both noninferiority and superiority. These findings suggest that a shorter duration of DAPT may provide benefit, although given study limitations, additional research is needed in other populations.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02619760.
参考来源
- Watanabe H, Domei T, Morimoto T, et al. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. JAMA. 2019. PMID: 31237644. doi:10.1001/jama.2019.8145
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。